Home›Stock Screener›Anlon Healthcare

Anlon Healthcare Share Price Today | Stock Price & Anlon Healthcare Share Screener

AHCL Pharmaceuticals & Biotechnology
Live Share Price NSE
₹24.97
▼ -0.48 (-1.89%)
2026-11-19 00:00:00
Live Share Price BSE
₹24.94
▼ -0.50 (-1.97%)
2026-11-19 00:00:00

As of November 19, 2026, the live Anlon Healthcare share price (NSE: AHCL) is ₹24.97 on NSE and ₹24.94 on BSE, down 1.89% from the previous close, with shares trading between ₹24.80 and ₹25.77 in today's trading session, and a 52-week range of ₹13.11–₹154.70. Track Anlon Healthcare market cap to gauge the company's total market size. Use the Anlon Healthcare stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Anlon Healthcare opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹106 and net income of ₹17, with EBITDA of ₹25, an operating margin of 24.0% and a profit margin of 16.0%.

Anlon Healthcare Market Cap ₹1,358.55 Cr.
AHCL P/E Ratio (TTM) 33.00
Anlon Healthcare P/B Ratio 5.31
EPS (TTM) ₹6.11
Dividend Yield -
Debt to Equity 0.35
AHCL 52 Week High ₹154.70
Anlon Healthcare 52 Week Low ₹13.11
Operating Margin 24.00%
Profit Margin 16.04%
AHCL Revenue (TTM) ₹106.00
EBITDA ₹25.00
Net Income ₹17.00
Total Assets ₹374.00
Total Equity ₹255.00

Anlon Healthcare Share Price Chart

Track the current stock price of Anlon Healthcare with an interactive chart. Analyse AHCL share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Anlon Healthcare stock quote in one place.

The quote of ₹24.97 sits between the 52-week low of ₹13.11 and the 52-week high of ₹154.70, and the latest session moved -1.89% from the previous close.

Anlon Healthcare Company Profile - Fundamental Screener

Screen Anlon Healthcare company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for AHCL shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE0Y8W01025.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE0Y8W01025

Anlon Healthcare Balance Sheet Screener

Screen AHCL balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹374, up from ₹181 in 2025.

Latest statistics put total assets at ₹374 and shareholder funds at ₹255, with a leverage ratio of 0.35.

Item 2026 2025

Assets

Total Assets 374 181
Current Assets 0 0
Fixed Assets 58 23

Liabilities

Total Liabilities 0 0
Current Liabilities 12 41
Non-Current Liabilities 0 0

Shareholders' Equity

Total Equity 255 80
Share Capital 53 40
Reserves & Surplus 177 41

Anlon Healthcare Income Statement Screener - Profit & Revenue Analysis

Screen Anlon Healthcare income statement and profit fundamentals. Analyze AHCL quarterly results. Anlon Healthcare reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Sept, revenue was ₹106 and net profit was ₹17, equal to earnings per unit of ₹0.32, at an operating margin of 24%.

In that period expenses were ₹80, interest cost ₹1 and tax ₹6. The next period listed, 2026-Jun, shows revenue of ₹88 and net profit of ₹8.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar

Revenue and Expenses

Revenue 106 88 51 36 52 33 49
Expenses 80 72 36 23 39 27 32

Operating Costs and Margins

EBITDA 25 16 15 13 14 6 17
Operating Profit % 24.00% 18.00% 30.00% 35.00% 26.00% 19.00% 35.00%
Depreciation 1 1 0 0 0 0 1
Interest 1 1 1 2 1 1 1

Profit and Earnings

Profit Before Tax 24 14 14 11 12 5 16
Tax 6 5 3 6 3 2 -1
Net Profit 17 8 11 5 9 4 17
EPS 0.32 0.16 2.33 1.13 0.18 0.89 5.15

Anlon Healthcare Cash Flow Screener - Liquidity Fundamentals

Screen AHCL cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities used ₹59, and net cash flow was an inflow of ₹23.

Over the same period, investing activities used ₹36 and financing activities provided ₹118.

Item 2026-March 2025-March

Cash from Operations and Investing

Operating Activities -59 -22
Investing Activities -36 2

Financing and Net Cash

Financing Activities 118 19
Net Cash Flow 23 -1

Anlon Healthcare Shareholding Pattern Screener

See Anlon Healthcare shareholding pattern with promoter, FII, and DII holdings. Check Anlon Healthcare promoter holding and ownership changes for AHCL on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 52.68%, foreign institutions 0.32%, domestic institutions 4.60% and the public 24.38%, spread across 12,484 shareholders.

The shareholder count was 12,484 in 2026-Mar, compared with 34,671 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Apr 2025-Jun 2025-Aug 2025-Sept 2025-Dec

Promoter Holding

Promoter Holding 52.68% 52.68% 52.68% 70.26% 52.68% 70.26% 52.68% 52.68%

Institutional Investors

FII Holding 0.32% 1.67% 1.00% 0.00% 14.42% 0.00% 0.00% 0.23%
DII Holding 4.60% 1.22% 0.30% 0.00% 4.35% 0.00% 2.83% 4.49%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 24.38% 26.19% 29.24% 0.00% 14.64% 0.00% 20.73% 23.58%
Other Holding 18.02% 18.24% 16.78% 29.74% 13.92% 29.74% 23.75% 19.02%
Shareholder Count 12,484 34,671 81,356 131 9,125 135 9,126 11,412

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Anlon Healthcare. Anlon Healthcare dividend yield can be compared with peers and other stocks in the market.

No dividends declared by Anlon Healthcare.

Anlon Healthcare Stock Index Membership - Nifty & Sensex

See which indices include Anlon Healthcare stock. Check AHCL index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Anlon Healthcare is not part of any tracked indices.
Only major market indices are tracked in our system.

Anlon Healthcare Market Events Screener - Corporate Actions

Get Anlon Healthcare corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Anlon Healthcare stock events that may affect AHCL share price, along with derivatives, futures and options activity and sector gainers.

8 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated October 29, 2026, with a record date of October 29, 2026.

It is followed by Annual General Meeting dated September 5, 2026 and Quarterly Result Announcement dated July 30, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-10-29 2026-10-29 Quarterly Result Announcement NA -4.38%
2026-09-05 2026-09-05 Annual General Meeting NA 8.36%
2026-07-30 2026-07-30 Quarterly Result Announcement NA 5.86%
2026-05-29 2026-05-29 Quarterly Result Announcement NA 2.59%
2026-04-24 2026-04-24 Split 2:10 29.43%
2026-04-24 2026-04-24 Bonus 1:1 18.26%
2026-02-09 2026-02-09 Quarterly Result Announcement NA 4.04%
2025-11-11 2025-11-11 Quarterly Result Announcement NA 2.44%

Anlon Healthcare Competitors Screener - Peer Stocks Comparison

Screen AHCL competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 448,676 40.80 61,674 12.69% 11,565 60.46
Divis Laboratories 295,997 87.70 11,067 13.95% 2,568 68.76
Torrent Pharmaceuticals 177,586 85.00 13,886 20.34% 2,138 47.23
Laurus Labs 126,325 89.90 6,868 22.01% 890 57.04
Zydus Life Science 120,119 27.60 27,658 17.64% 5,026 55.91
Dr Reddys Laboratories 115,854 41.80 35,059 3.90% 4,158 71.26
Cipla 112,131 39.50 29,045 2.24% 3,870 53.06
Mankind Pharma 107,805 47.90 14,636 14.85% 1,938 61.37
Aurobindo Pharma 103,229 25.80 34,145 5.56% 3,503 60.39
Lupin 89,172 17.30 29,039 26.75% 5,356 39.39

Anlon Healthcare Company Announcements - News & Reports Screener

Screen AHCL latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 6, 2026.

The next most recent announcements are dated November 3, 2026 and October 31, 2026.

Date Update Actions
2026-11-06 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-11-03 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-10-31 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-10-30 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-10-29 Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30 2026 -
2026-10-29 Board Meeting Outcome for For Consider And Approve Unaudited Standalone And Consolidated Financial Statement For The Quarter Ended September 30 2026 -
2026-10-29 Announcement Regarding To Receive In- Principle Approval From Stock Exchange As Per Reg. 29 Of SEBI (LODR) Regulation 2015 -
2026-10-26 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-24 Board Meeting Intimation for Consider And Approve The Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30 2026. -
2026-10-19 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-10-13 Board Meeting Outcome for Outcome Of Board Meeting Of ANLON HEALTHCARE LIMITED -
2026-09-29 Board Meeting Intimation for Companys Business Expansion Plans In India And/Or Overseas And The Raising Of Funds/ Financing Thereof In One Or More Tranches -
2026-09-28 Closure of Trading Window -
2026-09-24 Intimation Of Participation In Arihant Capital BHARAT CONNECT CONFERENCE RISING STARS 2026 Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-09-21 Announcement For Incorporation Of Foreign Subsidiary Of The Company -
2026-09-21 Announcement As Per Regulation 30 Of SEBI LODR. -
2026-09-17 Clarification On Price Movement -
2026-09-16 Clarification sought from Anlon Healthcare Ltd -
2026-09-15 Announcement under Regulation 30 (LODR)-Credit Rating -
2026-09-07 Shareholder Meeting / Postal Ballot-Outcome of AGM -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹24.97, within a 52-week range of ₹13.11 to ₹154.70. The P/E ratio is 33.00 and the P/B ratio is 5.31, with earnings per unit of ₹6.11. Market capitalisation stands at ₹1,358.55 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 2 balance sheet periods, 7 income statement periods, 2 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.